CHEST Bridging Specialties™ · LCS AFP
Lung Cancer Screening Eligibility Tool
Verified criteria: CHEST 2021 · USPSTF 2021 · NCCN v1.2026 · ACS 2023 · CMS NCD 210.14
Verified criteria
5 output states
Self-contained · No external calls
Patient Information
(packs per day) × (years smoked) — or enter directly below
packs / day
×
years smoked
= Pack-years:
✓
Eligible for Annual LCS
Meets USPSTF 2021 & CHEST 2021 criteria — covered at $0 with documented SDM
| Guideline | Eligible? | Coverage |
|---|---|---|
| USPSTF 2021 | ✓ | $0 with documented SDM · ACA §2713 |
| CHEST 2021 | ✓ | Aligns with USPSTF coverage |
| ACS 2023 | ✓ | No quit-year restriction |
| NCCN v1.2026 | ✓ | Category A |
| Medicare (CMS NCD) | ✓ | Covered ages 50–77 |
Next steps
Conduct and document SDM session (covers 6 required elements). Order LDCT: CPT 71271 · ICD-10 Z87.891 + Z12.2. ACR-accredited facility only. Do NOT order "standard CT chest."
◐
Eligible under ACS 2023 — Coverage Gap
Quit >15 years ago: ACS/NCCN qualify; USPSTF does not → payer may not cover
| Guideline | Eligible? | Note |
|---|---|---|
| USPSTF 2021 | ✗ | Quit >15 yrs exceeds cutoff |
| CHEST 2021 | ✗ | Same cutoff as USPSTF |
| ACS 2023 | ✓ | No quit-year restriction |
| NCCN v1.2026 | ✓ | No quit-year restriction |
| Medicare (CMS NCD) | ✗ | USPSTF governs coverage |
Clinical guidance
This patient is clinically eligible per ACS 2023 and NCCN v1.2026 but may lack insurance coverage under USPSTF-based payer policies. Discuss in SDM. Consider PLCOm2012 risk modeling to support the case. Document thoroughly.
⚑
Eligible under NCCN Group 2 (Expanded)
Does not fully meet USPSTF — additional risk factors support screening via NCCN v1.2026
| Guideline | Eligible? | Note |
|---|---|---|
| USPSTF 2021 | ✗ | Does not meet all three criteria |
| CHEST 2021 | ✗ | Aligns with USPSTF |
| ACS 2023 | ~ | Depends on specific criteria |
| NCCN v1.2026 | ✓ | Group 2: ≥20-yr smoking + ≥1 risk factor |
| Medicare (CMS NCD) | ✗ | USPSTF governs Medicare coverage |
Clinical guidance
Consider PLCOm2012 risk model (≥1.5% = supports eligibility). Apply NCCN Group 2 criteria in SDM conversation. Payer coverage may not follow NCCN — verify before ordering. Document risk discussion thoroughly.
!
Borderline — Individualized SDM Recommended
Patient approaches eligibility thresholds; shared decision-making indicated
Clinical guidance
This patient does not currently meet standard eligibility criteria but has risk factors warranting discussion. Consider PLCOm2012 model, occupational and family history assessment, and individualized SDM — especially for ages 45–49 with significant smoking history and additional risk factors (African American race, COPD, occupational or family exposure).
✗
Not Currently Eligible for Routine LCS
Does not meet criteria under any major guideline at this time
USPSTF 2021
Ineligible
CHEST 2021
Ineligible
ACS 2023
Ineligible
NCCN v1.2026
Ineligible
Continue tobacco cessation counseling
Document smoking history and reassess eligibility annually. If risk factors develop (COPD, family history, occupational exposure), reassess using NCCN Group 2 criteria.
CHEST Bridging Specialties™ · LCS AFP · Lung Cancer Screening Eligibility Tool
Sources: USPSTF 2021 · CHEST 2021 · ACS 2023 · NCCN v1.2026 · CMS NCD 210.14
For educational use only. Not a substitute for clinical judgment.
Sources: USPSTF 2021 · CHEST 2021 · ACS 2023 · NCCN v1.2026 · CMS NCD 210.14
For educational use only. Not a substitute for clinical judgment.
Stay Informed
To receive updates as soon as the new dates are confirmed, please share your email.
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
Thank you!
✅ You’re confirmed!
Thank you for confirming.
You’ll receive reminder emails for the next LGS CME/CE session, including full access details.
We look forward to your participation.
Thank you for confirming.
You’ll receive reminder emails for the next LGS CME/CE session, including full access details.
We look forward to your participation.